SCHEDULE 13D/A: Vida Ventures Significantly Reduces Stake in Vigil Neuroscience, Inc.
Beneficial Ownership Update
Vida Ventures, a key institutional investor, has filed an Amendment No. 2 to its Schedule 13D, disclosing a substantial reduction in its beneficial ownership of Vigil Neuroscience, Inc. common stock.
Summary
- This document is Amendment No. 2 to the Schedule 13D originally filed on February 10, 2023, and amended on October 9, 2024.
- The Reporting Persons are Vida Ventures III, L.P., Vida Ventures III-A, L.P., and Vida Ventures GP III, L.L.C.
- Stefan Vitorovic, previously a reporting person, is no longer a member of Vida III GP and is therefore no longer a Reporting Person.
- As of June 6, 2025, the aggregate beneficial ownership by Vida Ventures GP III, L.L.C. (representing all reporting persons) is 2,842,000 shares of Vigil Neuroscience, Inc. Common Stock.
- This aggregate beneficial ownership represents 6.1% of the Issuer's Common Stock, based on 46,671,534 shares outstanding as of April 30, 2025.
- On June 5, 2025, Vida III sold 594,558 shares at a weighted average price of $7.8838 per share, totaling $4,687,386.65.
- On June 5, 2025, Vida III-A sold 1,371 shares at a weighted average price of $7.8838 per share, totaling $10,805.25.
- On June 6, 2025, Vida III sold 1,574,371 shares at a weighted average price of $7.8755 per share, totaling $12,398,957.24.
- On June 6, 2025, Vida III-A sold 3,629 shares at a weighted average price of $7.8755 per share, totaling $28,581.76.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a major institutional investor significantly reducing its stake, which can be perceived as a bearish signal by the market.
Negatives
- A significant reduction in beneficial ownership by a major institutional investor (Vida Ventures) could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the Issuer's future performance or strategic direction.
Industry Context
This filing primarily concerns a change in beneficial ownership by an institutional investor and does not provide broader industry context or trends.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Reporting Person (member of Vida III GP) | Stefan Vitorovic | N/A | N/A | Stefan Vitorovic is no longer a member of Vida III GP and, accordingly, is no longer a Reporting Person. |
Stakeholder Impact
- Shareholders: The reduction in stake by a significant institutional investor may lead to negative market sentiment and potential downward pressure on the stock price.
- Company Management: May need to address investor concerns regarding the divestment by a major holder.
Key Dates
| Date | Description |
|---|---|
| 02/10/2023 | Original Schedule 13D filed by the Reporting Persons with the SEC. |
| 10/09/2024 | Amendment No. 1 to the Schedule 13D filed with the SEC. |
| 04/30/2025 | Date as of which 46,671,534 shares of the Issuer's Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 05/07/2025 | Date the Issuer's quarterly report on Form 10-Q for the quarter ended March 31, 2025, was filed with the SEC. |
| 06/05/2025 | Date of event requiring filing of this statement; Vida III and Vida III-A sold shares of Common Stock. |
| 06/06/2025 | Date as of which beneficial ownership information is reported; Vida III and Vida III-A sold additional shares of Common Stock. |
| 06/09/2025 | Date the Amendment No. 2 was signed by Jean-Philippe Kouakou-Zebouah, Managing Member of Vida Ventures GP III, L.L.C. |
Keywords
Vigil Neuroscience, SEC filing, Schedule 13D, beneficial ownership, Vida Ventures, stake reduction, common stock, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.